Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$22.56

-7.32 (-24.50%)

08:41
11/25/16
11/25
08:41
11/25/16
08:41

Juno still has significant opportunity in 'no-option population,' says Maxim

Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.

  • 03

    Dec

  • 03

    Dec

JUNO Juno Therapeutics
$22.56

-7.32 (-24.50%)

11/23/16
JPMS
11/23/16
NO CHANGE
Target $34
JPMS
Neutral
Juno Therapeutics price target lowered to $34 from $39 at JPMorgan
JPMorgan analyst Cory Kasimov lowered his price target for Juno Therapeutics to $34 after the company voluntarily placed the JCAR015 pivotal ROCKET study on clinical hold. The analyst reiterates a Neural rating on the shares.
11/25/16
RHCO
11/25/16
DOWNGRADE
RHCO
Hold
Juno Therapeutics downgraded to Hold from Buy at SunTrust
11/25/16
SBSH
11/25/16
NO CHANGE
Target $34
SBSH
Buy
Citi still bullish on Juno's technology despite clinical hold
Citi analyst Robyn Karnauskas says she remains bullish on Juno Therapeutics' technology after the company voluntarily placed its JCAR015 ROCKET program on clinical hold following cerebral edema in two patients last week. Juno has the best data in both adult and pediatric acute lymphoblastic leukemia, Karnauskas told investors Wednesday in a research note. She expects the company's therapies will get used despite the safety risks and believes Juno will be able to find ways to slow the rate of cell proliferation and reduce toxicity. The analyst lowered her price target for Juno shares to $34 from $45 and kept a Buy rating on the name. Juno closed Wednesday down $7.32 to $22.56.
11/25/16
11/25/16
DOWNGRADE
Target $25

Hold
Juno Therapeutics downgraded to Hold at SunTrust
As previously reported, SunTrust analyst Peter Lawson downgraded Juno Therapeutics to Hold from Buy due to the reduced visibility and increased uncertainty that comes from the two additional deaths in the company's ROCKET trial of JCAR015. Citing the renewed issues with JCAR015, Lawson decreased his probability of success across the company's pipeline and lowered his price target for Juno shares to $25 from $48.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.